Equities

Faron Pharmaceuticals Oy

FARN:LSE

Faron Pharmaceuticals Oy

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)263.00
  • Today's Change13.00 / 5.20%
  • Shares traded48.11k
  • 1 Year change-11.45%
  • Beta-0.1772
Data delayed at least 20 minutes, as of May 20 2024 09:36 BST.
More ▼

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-26.49m
  • Incorporated2006
  • Employees34.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Scancell Holdings Plc0.00-11.32m93.73m51.0093.73m51.00
Futura Medical PLC3.10m-6.51m119.68m12.00119.68m12.00
Animalcare Group Plc74.35m1.20m137.65m220.00137.65m220.00
Allergy Therapeutics plc53.26m-50.22m154.91m635.00154.91m635.00
Avacta Group Plc16.03m-42.08m155.29m120.00155.29m120.00
Faron Pharmaceuticals Oy0.00-26.49m179.63m34.00179.63m34.00
4Basebio PLC354.00k-6.28m180.55m--180.55m--
hVIVO PLC56.04m16.12m187.10m274.00187.10m274.00
Alliance Pharma plc170.05m-7.06m191.30m249.00191.30m249.00
Bioventix PLC13.60m8.67m228.36m16.00228.36m16.00
Data as of May 20 2024. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

12.65%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 31 Jan 20242.84m3.94%
Fj�rde AP-fondenas of 31 Oct 20232.58m3.58%
OP Asset Management Ltd.as of 31 Dec 20232.00m2.78%
Sp-Fund Management Co. Ltd.as of 30 Apr 2024800.04k1.11%
Fondita Fund Management Co. Ltd.as of 31 Mar 2024330.49k0.46%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023159.68k0.22%
Danske Bank A/S (Investment Management Finland)as of 27 Mar 2024140.40k0.20%
Aktia Varainhoito Oyas of 31 Oct 2021117.37k0.16%
Janus Henderson Investors UK Ltd.as of 31 Mar 2024100.00k0.14%
BG Fund Management Luxembourg SAas of 31 Dec 202341.74k0.06%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.